{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:25:07Z","timestamp":1772036707215,"version":"3.50.1"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"19","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Leprosy (Hansen\u2019s disease) is a neglected tropical disease affecting millions\nof people globally. The combined formulations of dapsone, rifampicin and clofazimine\n(multidrug therapy, MDT) is only supportive in the early stage of detection, while \u201creemergence\u201d is\na significant problem. Thus, there is still a need to develop newer antileprosy molecules either of\nnatural or semi-synthetic origin.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The review intends to present the latest developments in the disease prevalence, available\ntherapeutic interventions and the possibility of identifying new molecules from phytoextracts.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Literature on the use of plant extracts and their active components to treat leprosy was\nsearched. Selected phytoconstituents were subjected to molecular docking study on both wild and\nmutant types of the Mycobacterium leprae. Since the M. leprae dihydropteroate synthase (DHPS) is\nnot available in the protein data bank (PDB), it was modelled by the homology model method and\nvalidated with the Ramachandran plot along with other bioinformatics approaches. Two mutations\nwere introduced at codons 53 (Thr to Ile) and 55 (Pro to Leu) for docking against twenty-five selected\nphytoconstituents reported from eight plants that recorded effective anti-leprosy activity. The\nchemical structure of phytochemicals and the standard dapsone structure were retrieved from the\nPubChem database and prepared accordingly for docking study with the virtual-screening platform\nof PyRx-AutoDock 4.1.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Based on the docking score (kcal\/mol), most of the phytochemicals exhibited a higher\ndocking score than dapsone. Asiaticoside, an active saponin (-11.3, -11.2 and -11.2 kcal\/mol), was\nproved to be the lead phytochemical against both wild and mutant types DHPS. Some other useful\nphytoconstituents include echinocystic acid (-9.6, -9.5 and -9.5 kcal\/mol), neobavaisoflavone (-9.2,\n-9.0 and -9.0 kcal\/mol), boswellic acid (-8.90, -8.90 and -8.90 kcal\/mol), asiatic acid (-8.9, -8.8 and\n-8.9 kcal\/mol), corylifol A (-8.8, 8.0, and -8.0), etc. Overall, the computational predictions support\nthe previously reported active phytoextracts of Centella asiatica (L.) Urban, Albizia amara (Roxb.)\nBoivin, Boswellia serrata Roxb. and Psoralea corylifolia L. to be effective against leprosy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>A very small percentage of well-known plants have been evaluated scientifically for\nantileprosy activity. Further in vivo experiments are essential to confirm anti-leprosy properties of\nsuch useful phytochemicals.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026621666210909162435","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T04:43:37Z","timestamp":1631249017000},"page":"1611-1625","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Disease Burden and Current Therapeutical Status of Leprosy with Special\nEmphasis on Phytochemicals"],"prefix":"10.2174","volume":"22","author":[{"given":"Shasank Sekhar","family":"Swain","sequence":"first","affiliation":[{"name":"Division of Microbiology &amp; NCDs, ICMR-Regional Medical Research Centre, Bhubaneswar, 751023, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunanidhi","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Zoology, Utkal University, Vani Vihar, Bhubaneswar-751004, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravati Kumari","family":"Mahapatra","sequence":"additional","affiliation":[{"name":"Department of Zoology, Utkal University, Vani Vihar, Bhubaneswar-751004, Odisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujogya Kumar","family":"Panda","sequence":"additional","affiliation":[{"name":"Department of Zoology, Utkal University, Vani Vihar, Bhubaneswar-751004, Odisha, India"},{"name":"Centre of Environment, Climate Change and Public Health, RUSA 2.0, Utkal University, Vani Vihar, Bhubaneswar, 751004, Odisha, IndiaOdisha, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2019","unstructured":"Leprosy: new data show steady decline in new cases. WHOAvailable from: \n(Assessed\non 24 April 2021)2019"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.47276\/lr.83.3.221","volume":"83","author":"Gelber R.H.","year":"2012","unstructured":"Gelber R.H.; Grosset J.; The chemotherapy of leprosy: An interpretive history. Lepr Rev 2012,83(3),221-240","journal-title":"Lepr Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0140-6736(05)60888-4","volume":"349","author":"Cambau E.","year":"1997","unstructured":"Cambau E.; Perani E.; Guillemin I.; Jamet P.; Ji B.; Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet 1997,349(9045),103-104","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/QCO.0b013e3283638b04","volume":"26","author":"Polycarpou A.","year":"2013","unstructured":"Polycarpou A.; Walker S.L.; Lockwood D.N.J.; New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis 2013,26(5),413-419","journal-title":"Curr Opin Infect Dis"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001869","volume":"6","author":"Cogen A.L.","year":"2012","unstructured":"Cogen A.L.; Walker S.L.; Roberts C.H.; Hagge D.A.; Neupane K.D.; Khadge S.; Lockwood D.N.; Human beta-defensin 3 is up-regulated in cutaneous leprosy type 1 reactions. PLoS Negl Trop Dis 2012,6(11)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/IPC.0b013e3181deba2a","volume":"18","author":"Graham A.","year":"2010","unstructured":"Graham A.; Furlong S.; Margoles L.M.; Clinical management of leprosy reactions. Infect Dis Clin Pract 2010,18,235-238","journal-title":"Infect Dis Clin Pract"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1574-695X.2008.00491.x","volume":"55","author":"Parkash O.","year":"2009","unstructured":"Parkash O.; Classification of leprosy into multibacillary and paucibacillary groups: An analysis. FEMS Immunol Med Microbiol 2009,55(1),1-5","journal-title":"FEMS Immunol Med Microbiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/0019-5154.147791","volume":"60","author":"Kumaran S.M.","year":"2015","unstructured":"Kumaran S.M.; Bhat I.P.; Madhukara J.; Rout P.; Elizabeth J.; Comparison of bacillary index on slit skin smear with bacillary index of granuloma in leprosy and its relevance to present therapeutic regimens. Indian J Dermatol 2015,60(1),51-54","journal-title":"Indian J Dermatol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2217\/fmb.10.173","volume":"6","author":"Pinheiro R.O.","year":"2011","unstructured":"Pinheiro R.O.; de Souza Salles J.; Sarno E.N.; Sampaio E.P.; Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: An overview. Future Microbiol 2011,6(2),217-230","journal-title":"Future Microbiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1128\/AAC.33.12.2115","volume":"33","author":"Franzblau S.G.","year":"1989","unstructured":"Franzblau S.G.; Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system. Antimicrob Agents Chemother 1989,33(12),2115-2117","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5935\/0305-7518.19920016","volume":"63","author":"Franzblau S.G.","year":"1992","unstructured":"Franzblau S.G.; Biswas A.N.; Jenner P.; Colston M.J.; Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for in vitro screening of antileprosy agents. Lepr Rev 1992,63(2),125-133","journal-title":"Lepr Rev"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/idoj.IDOJ_260_18","volume":"10","author":"Sengupta U.","year":"2019","unstructured":"Sengupta U.; Recent laboratory advances in diagnostics and monitoring response to treatment in leprosy. Indian Dermatol Online J 2019,10(2),106-114","journal-title":"Indian Dermatol Online J"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002655","volume":"8","author":"Martinez A.N.","year":"2014","unstructured":"Martinez A.N.; Talhari C.; Moraes M.O.; Talhari S.; PCR-based techniques for leprosy diagnosis: from the laboratory to the clinic. PLoS Negl Trop Dis 2014,8(4)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=14","year":"2018","unstructured":"Global leprosy update, 2018: moving towards a leprosy\nfree world WHOAvailable from:\n(Assessed on 24 April 2021)2018"},{"key":"ref=15","year":"2021","unstructured":"Leprosy (Hansen\u2019s disease). WHOAvailable from: 2021"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/idoj.IDOJ_282_17","volume":"9","author":"Rao P.N.","year":"2018","unstructured":"Rao P.N.; Suneetha S.; Situation of leprosy in India and its future implications. Indian Dermatol Online J 2018,9(2),83-89","journal-title":"Indian Dermatol Online J"},{"key":"ref=17","first-page":"170","volume":"80","author":"Jing Z.","year":"2009","unstructured":"Jing Z.; Zhang R.; Zhou D.; Chen J.; Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy. Lepr Rev 2009,80(2),170-176","journal-title":"Lepr Rev"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.cmi.2018.02.022","volume":"24","author":"Cambau E.","year":"2018","unstructured":"Cambau E.; Saunderson P.; Matsuoka M.; Cole S.T.; Kai M.; Suffys P.; Rosa P.S.; Williams D.; Gupta U.D.; Lavania M.; Cardona-Castro N.; Miyamoto Y.; Hagge D.; Srikantam A.; Hongseng W.; Indropo A.; Vissa V.; Johnson R.C.; Cauchoix B.; Pannikar V.K.; Cooreman E.A.W.D.; Pemmaraju V.R.R.; Gillini L.; Antimicrobial resistance in leprosy: Results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. Clin Microbiol Infect 2018,24(12),1305-1310","journal-title":"Clin Microbiol Infect"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/cid\/cit628","volume":"58","author":"Williams D.L.","year":"2014","unstructured":"Williams D.L.; Lewis C.; Sandoval F.G.; Robbins N.; Keas S.; Gillis T.P.; Scollard D.M.; Drug resistance in patients with leprosy in the United States. Clin Infect Dis 2014,58(1),72-73","journal-title":"Clin Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1128\/JCM.06561-11","volume":"50","author":"da Silva Rocha A.","year":"2012","unstructured":"da Silva Rocha A.; Cunha Md.; Diniz L.M.; Salgado C.; Aires M.A.; Nery J.A.; Gallo E.N.; Miranda A.; Magnanini M.M.; Matsuoka M.; Sarno E.N.; Suffys P.N.; de Oliveira M.L.; Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients. J Clin Microbiol 2012,50(6),1912-1917","journal-title":"J Clin Microbiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"9838","DOI":"10.1002\/jcb.27304","volume":"119","author":"Swain S.S.","year":"2018","unstructured":"Swain S.S.; Paidesetty S.K.; Dehury B.; Sahoo J.; Vedithi S.C.; Mahapatra N.; Hussain T.; Padhy R.N.; Molecular docking and simulation study for synthesis of alternative dapsone derivative as a newer antileprosy drug in multidrug therapy. J Cell Biochem 2018,119(12),9838-9852","journal-title":"J Cell Biochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1128\/AAC.01212-10","volume":"55","author":"Nakata N.","year":"2011","unstructured":"Nakata N.; Kai M.; Makino M.; Mutation analysis of the Mycobacterium leprae folP1 gene and dapsone resistance. Antimicrob Agents Chemother 2011,55(2),762-766","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1574-6968.1999.tb13737.x","volume":"177","author":"Kai M.","year":"1999","unstructured":"Kai M.; Matsuoka M.; Nakata N.; Maeda S.; Gidoh M.; Maeda Y.; Hashimoto K.; Kobayashi K.; Kashiwabara Y.; Diaminodiphenylsulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Microbiol Lett 1999,177(2),231-235","journal-title":"FEMS Microbiol Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.47276\/lr.85.3.177","volume":"85","author":"Lavania M.","year":"2014","unstructured":"Lavania M.; Jadhav R.S.; Chaitanya V.S.; Turankar R.; Selvasekhar A.; Das L.; Darlong F.; Hambroom U.K.; Kumar S.; Sengupta U.; Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India. Lepr Rev 2014,85(3),177-185","journal-title":"Lepr Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4269\/ajtmh.19-0390","volume":"102","author":"Mahajan N.P.","year":"2020","unstructured":"Mahajan N.P.; Lavania M.; Singh I.; Nashi S.; Preethish-Kumar V.; Vengalil S.; Polavarapu K.; Pradeep-Chandra-Reddy C.; Keerthipriya M.; Mahadevan A.; Yasha T.C.; Nandeesh B.N.; Gnanakumar K.; Parry G.J.; Sengupta U.; Nalini A.; Evidence for Mycobacterium leprae drug resistance in a large cohort of leprous neuropathy patients from India. Am J Trop Med Hyg 2020,102(3),547-552","journal-title":"Am J Trop Med Hyg"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1489\/1544-581X(2004)72<468:AMACIT>2.0.CO;2","volume":"72","author":"Zhang L.","year":"2004","unstructured":"Zhang L.; Namisato M.; Matsuoka M.; A mutation at codon 516 in the rpoB gene of Mycobacterium leprae confers resistance to rifampin. Int J Lepr Other Mycobact Dis 2004,72(4),468-472","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"ref=27","first-page":"36","volume":"82","author":"Sekar B.","year":"2011","unstructured":"Sekar B.; Arunagiri K.; Kumar B.N.; Narayanan S.; Menaka K.; Oommen P.K.; Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy. Lepr Rev 2011,82(1),36-45","journal-title":"Lepr Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1038\/s41598-018-23423-1","volume":"8","author":"Vedithi S.C.","year":"2018","unstructured":"Vedithi S.C.; Malhotra S.; Das M.; Daniel S.; Kishore N.; George A.; Arumugam S.; Rajan L.; Ebenezer M.; Ascher D.B.; Arnold E.; Blundell T.L.; Structural implications of mutations conferring rifampin resistance in Mycobacterium leprae. Sci Rep 2018,8(1),5016","journal-title":"Sci Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.05890-11","volume":"56","author":"Yokoyama K.","year":"2012","unstructured":"Yokoyama K.; Kim H.; Mukai T.; Matsuoka M.; Nakajima C.; Suzuki Y.; Amino acid substitutions at position 95 in GyrA can add fluoroquinolone resistance to Mycobacterium leprae. Antimicrob Agents Chemother 2012,56(2),697-702","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","first-page":"452","volume":"68","author":"Matsuoka M.","year":"2000","unstructured":"Matsuoka M.; Kashiwabara Y.; Namisato M.; A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Int J Lepr Other Mycobact Dis 2000,68(4),452-455","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.3201\/eid2408.180033","volume":"24","author":"Williams D.L.","year":"2018","unstructured":"Williams D.L.; Araujo S.; Stryjewska B.M.; Scollard D.; Dapsone resistance in leprosy patients originally from American Samoa, United States, 2010-2012. Emerg Infect Dis 2018,24(8),1584-1585","journal-title":"Emerg Infect Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12879-019-4665-0","volume":"20","author":"Lazo-Porras M.","year":"2020","unstructured":"Lazo-Porras M.; Prutsky G.J.; Barrionuevo P.; Tapia J.C.; Ugarte-Gil C.; Ponce O.J.; Acu\u00f1a-Villaordu\u00f1a A.; Domecq J.P.; De la Cruz-Luque C.; Prokop L.J.; M\u00e1laga G.; World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: A systematic review and meta-analysis. BMC Infect Dis 2020,20(1),62","journal-title":"BMC Infect Dis"},{"key":"ref=33","first-page":"1","volume":"137","author":"Smith W.C.","year":"2013","unstructured":"Smith W.C.; Leprosy: Making good progress but hidden challenges remain. Indian J Med Res 2013,137(1),1-3","journal-title":"Indian J Med Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/ijmy.ijmy_70_17","volume":"6","author":"Naaz F.","year":"2017","unstructured":"Naaz F.; Mohanty P.S.; Bansal A.K.; Kumar D.; Gupta U.D.; Challenges beyond elimination in leprosy. Int J Mycobacteriol 2017,6(3),222-228","journal-title":"Int J Mycobacteriol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1086\/324623","volume":"34","author":"Cambau E.","year":"2002","unstructured":"Cambau E.; Bonnafous P.; Perani E.; Sougakoff W.; Ji B.; Jarlier V.; Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 2002,34(1),39-45","journal-title":"Clin Infect Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jinf.2004.03.012","volume":"50","author":"You E.Y.","year":"2005","unstructured":"You E.Y.; Kang T.J.; Kim S.K.; Lee S.B.; Chae G.T.; Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect 2005,50(1),6-11","journal-title":"J Infect"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/0019-5154.108029","volume":"58","author":"Malathi M.","year":"2013","unstructured":"Malathi M.; Thappa D.M.; Fixed-duration therapy in leprosy: Limitations and opportunities. Indian J Dermatol 2013,58(2),93-100","journal-title":"Indian J Dermatol"},{"key":"ref=38","first-page":"47","volume":"45","author":"Parascandola J.","year":"2003","unstructured":"Parascandola J.; Chaulmoogra oil and the treatment of leprosy. Pharm Hist 2003,45(2),47-57","journal-title":"Pharm Hist"},{"key":"ref=39","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/181089","author":"Bhat R.M.","year":"2012","unstructured":"Bhat R.M.; Prakash C.; Leprosy: An overview of pathophysiology. Interdiscip Perspect Infect Dis 2012","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1128\/CMR.00079-13","volume":"28","author":"White C.","year":"2015","unstructured":"White C.; Franco-Paredes C.; Leprosy in the 21st century. Clin Microbiol Rev 2015,28(1),80-94","journal-title":"Clin Microbiol Rev"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.47276\/lr.78.3.216","volume":"78","author":"Deps P.D.","year":"2007","unstructured":"Deps P.D.; Nasser S.; Guerra P.; Simon M.; Birshner, Rde.C.; Rodrigues, L.C. Adverse effects from multi-drug therapy in leprosy: A Brazilian study. Lepr Rev 2007,78(3),216-222","journal-title":"Lepr Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/CPAA.S135846","volume":"9","author":"Guragain S.","year":"2017","unstructured":"Guragain S.; Upadhayay N.; Bhattarai B.M.; Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: A retrospective study. Clin Pharmacol 2017,9,73-78","journal-title":"Clin Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1017\/S0950268818002145","volume":"146","author":"Gomes Lima Santos N.","year":"2018","unstructured":"Gomes Lima Santos N.; Perez Pereira Ramos K.; Shanmugam S.; Oliveira de Carvalho F.; Garcez Barreto Teixeira L.; Ramos Silva \u00c9.; de Vasconcelos Cerqueira-Braz J.; Santos Nunes P.; Antunes de Souza Ara\u00fajo A.; New therapeutic patents used for the treatment of leprosy: A review. Epidemiol Infect 2018,146(14),1746-1749","journal-title":"Epidemiol Infect"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clindermatol.2014.07.009","volume":"33","author":"Richardus J.H.","year":"2015","unstructured":"Richardus J.H.; Oskam L.; Protecting people against leprosy: chemoprophylaxis and immunoprophylaxis. Clin Dermatol 2015,33(1),19-25","journal-title":"Clin Dermatol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1473-3099(06)70412-1","volume":"6","author":"Setia M.S.","year":"2006","unstructured":"Setia M.S.; Steinmaus C.; Ho C.S.; Rutherford G.W.; The role of BCG in prevention of leprosy: A meta-analysis. Lancet Infect Dis 2006,6(3),162-170","journal-title":"Lancet Infect Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1586\/erv.09.161","volume":"9","author":"Merle C.S.","year":"2010","unstructured":"Merle C.S.; Cunha S.S.; Rodrigues L.C.; BCG vaccination and leprosy protection: Review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010,9(2),209-222","journal-title":"Expert Rev Vaccines"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.puhe.2004.04.007","volume":"119","author":"Zodpey S.P.","year":"2005","unstructured":"Zodpey S.P.; Ambadekar N.N.; Thakur A.; Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of leprosy: A population-based case-control study in Yavatmal District, India. Public Health 2005,119(3),209-216","journal-title":"Public Health"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.1016\/j.vaccine.2007.07.032","volume":"25","author":"Rodrigues L.C.","year":"2007","unstructured":"Rodrigues L.C.; Kerr-Pontes L.R.S.; Frietas M.V.C.; Barreto M.L.; Long lasting BCG protection against leprosy. Vaccine 2007,25(39-40),6842-6844","journal-title":"Vaccine"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41541-018-0050-z","volume":"3","author":"Duthie M.S.","year":"2018","unstructured":"Duthie M.S.; Pena M.T.; Ebenezer G.J.; Gillis T.P.; Sharma R.; Cunningham K.; Polydefkis M.; Maeda Y.; Makino M.; Truman R.W.; Reed S.G.; LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection. NPJ Vaccines 2018,3,12","journal-title":"NPJ Vaccines"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1016\/j.bbagen.2013.02.008","volume":"1830","author":"Cragg G.M.","year":"2013","unstructured":"Cragg G.M.; Newman D.J.; Natural products: A continuing source of novel drug leads. Biochim Biophys Acta 2013,1830(6),3670-3695","journal-title":"Biochim Biophys Acta"},{"key":"ref=51","year":"2013","unstructured":"WHO traditional medicine strategy: 2014-2023 WHOAvailable from: \n (Assessed on 24 April 2021)2013"},{"key":"ref=52","first-page":"55","volume":"4","author":"Ghosh G.","year":"2017","unstructured":"Ghosh G.; Traditional use of plants against leprosy in India: A review of the recent literature. J Innov Pharm Biol Sci 2017,4,55-64","journal-title":"J Innov Pharm Biol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"813","DOI":"10.5958\/0974-360X.2018.00153.1","volume":"11","author":"Dhevi V.V.","year":"2018","unstructured":"Dhevi V.V.; Potential medicinal plants to treat leprosy-A review. Res J Pharm Tech 2018,11,813-821","journal-title":"Res J Pharm Tech"},{"key":"ref=54","author":"Holzhey M.","year":"1992","unstructured":"Holzhey M.; Roth H.H.; Hoepfner V.; Use of Allicin - urotopin as internal drug for the treatment of infections and cancer PatentGer Offen - 4,024,155 1992","journal-title":"PatentGer Offen - 4,024,155"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1073\/pnas.71.8.3260","volume":"71","author":"White R.J.","year":"1974","unstructured":"White R.J.; Martinelli E.; Lancini G.; Ansamycin biogenesis: studies on a novel rifamycin isolated from a mutant strain of Nocardia mediterranei. Proc Natl Acad Sci USA 1974,71(8),3260-3264","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/clim.1999.4769","volume":"93","author":"Han S.S.","year":"1999","unstructured":"Han S.S.; Chung S.T.; Robertson D.A.; Ranjan D.; Bondada S.; Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 1999,93(2),152-161","journal-title":"Clin Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.etp.2010.03.001","volume":"63","author":"Naik S.R.","year":"2011","unstructured":"Naik S.R.; Thakare V.N.; Patil S.R.; Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property. Exp Toxicol Pathol 2011,63(5),419-431","journal-title":"Exp Toxicol Pathol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-2006-957444","volume":"64","author":"Shao Y.","year":"1998","unstructured":"Shao Y.; Ho C.T.; Chin C.K.; Badmaev V.; Ma W.; Huang M.T.; Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med 1998,64(4),328-331","journal-title":"Planta Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1038\/s41598-020-63913-9","volume":"10","author":"Swain S.S.","year":"2020","unstructured":"Swain S.S.; Paidesetty S.K.; Dehury B.; Das M.; Vedithi S.C.; Padhy R.N.; Computer-aided synthesis of dapsone-phytochemical conjugates against dapsone-resistant Mycobacterium leprae. Sci Rep 2020,10(1),6839","journal-title":"Sci Rep"},{"key":"ref=60","first-page":"131","volume":"81","author":"Gupta U.D.","year":"2009","unstructured":"Gupta U.D.; Katoch K.; Katoch V.M.; Study of rifampicin resistance and comparison of dapsone resistance of M. leprae in pre- and post-MDT era. Indian J Lepr 2009,81(3),131-134","journal-title":"Indian J Lepr"},{"key":"ref=61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004331","volume":"10","author":"Roset Bahmanyar E.","year":"2016","unstructured":"Roset Bahmanyar E.; Smith W.C.; Brennan P.; Cummings R.; Duthie M.; Richardus J.H.; Saunderson P.; Shwe T.; Rosen S.; Geluk A.; Leprosy diagnostic test development as a prerequisite towards elimination: Requirements from the user\u2019s perspective. PLoS Negl Trop Dis 2016,10(2)","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-0-387-70638-2","author":"Khare C.P.","year":"2007","unstructured":"Khare C.P.;  Indian medicinal plants: An illustrated dictionary 2007,199-201","journal-title":"Indian medicinal plants: An illustrated dictionary"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-8741(98)00141-X","volume":"65","author":"Shukla A.","year":"1999","unstructured":"Shukla A.; Rasik A.M.; Jain G.K.; Shankar R.; Kulshrestha D.K.; Dhawan B.N.; In vitro and in vivo wound healing activity of asiaticoside isolated from Centella asiatica. J Ethnopharmacol 1999,65(1),1-11","journal-title":"J Ethnopharmacol"},{"key":"ref=64","first-page":"177","volume":"70","author":"Chaudhuri S.","year":"1978","unstructured":"Chaudhuri S.; Ghosh S.; Chakraborty T.; Kundu S.; Hazra S.K.; Use of a common Indian herb \u201cMandukaparni\u201d in the treatment of leprosy (preliminary report). J Indian Med Assoc 1978,70(8),177-180","journal-title":"J Indian Med Assoc"},{"key":"ref=65","first-page":"116","volume":"53","author":"Tra N.H.","year":"2015","unstructured":"Tra N.H.; Nagan T.B.; Huong D.T.M.; Chemical constituents from fruits of Hydnocarpus hainanensis Merr. (Flacourtiaceae) in Vietnam. Vietnam J Chem 2015,53,116-119","journal-title":"Vietnam J Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1016\/j.bmc.2004.06.014","volume":"12","author":"Yin S.","year":"2004","unstructured":"Yin S.; Fan C.Q.; Wang Y.; Dong L.; Yue J.M.; Antibacterial prenylflavone derivatives from Psoralea corylifolia, and their structure-activity relationship study. Bioorg Med Chem 2004,12(16),4387-4392","journal-title":"Bioorg Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1248\/cpb.53.1054","volume":"53","author":"Zhao L.H.","year":"2005","unstructured":"Zhao L.H.; Wu M.H.; Xiang B.R.; Analysis of Psoralea corylifolia L. fruits in different regions. Chem Pharm Bull (Tokyo) 2005,53(8),1054-1057","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=68","first-page":"13","volume":"4","author":"Rajput S.J.","year":"2008","unstructured":"Rajput S.J.; Vijaya Z.; Pallavi R.; Studies on extraction, isolation and estimation of Psoralea corylifolia. Pharmacogn Mag 2008,4,13-18","journal-title":"Pharmacogn Mag"},{"key":"ref=69","first-page":"38","volume":"3","author":"Shinde A.N.","year":"2009","unstructured":"Shinde A.N.; Malpathak N.; Fulzele D.P.; Induced high frequency shoot regeneration and enhanced isoflevonces productin in Psoralea corylifolia. Rec Nat Prod 2009,3,38-45","journal-title":"Rec Nat Prod"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2021.1885495","author":"Swain S.S.","year":"2021","unstructured":"Swain S.S.; Singh S.R.; Sahoo A.; Hussain T.; Pati S.; Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: A molecular docking-simulation base assessment. J Biomol Struct Dyn 2021,1-14","journal-title":"J Biomol Struct Dyn"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2013.02.032","volume":"334","author":"Aqil F.","year":"2013","unstructured":"Aqil F.; Munagala R.; Jeyabalan J.; Vadhanam M.V.; Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett 2013,334(1),133-141","journal-title":"Cancer Lett"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2174\/1389200221666200103090757","volume":"20","author":"Rathaur P.","year":"2019","unstructured":"Rathaur P.; S R, J.K. Metabolism and Pharmacokinetics of Phytochemicals in the Human Body. Curr Drug Metab 2019,20(14),1085-1102","journal-title":"Curr Drug Metab"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1128\/AAC.38.7.1651","volume":"38","author":"Franzblau S.G.","year":"1994","unstructured":"Franzblau S.G.; Chan G.P.; Garcia-Ignacio B.G.; Chavez V.E.; Livelo J.B.; Jimenez C.L.; Parrilla M.L.; Calvo R.F.; Williams D.L.; Gillis T.P.; Clinical trial of fusidic acid for lepromatous leprosy. Antimicrob Agents Chemother 1994,38(7),1651-1654","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026621666210909162435","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/196321\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026621666210909162435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:48:52Z","timestamp":1691866132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/196321\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":73,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026621666210909162435","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-05-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}